NASDAQ:MGTA Magenta Therapeutics - MGTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.46 +0.02 (+4.52%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.43▼$0.4850-Day Range$0.36▼$1.3352-Week Range$0.32▼$3.62Volume932,225 shsAverage Volume1.39 million shsMarket Capitalization$27.98 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Magenta Therapeutics MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside837.7% Upside$4.33 Price TargetShort InterestHealthy1.59% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment-0.45Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.24) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector144th out of 1,055 stocksPharmaceutical Preparations Industry61st out of 519 stocks 3.1 Analyst's Opinion Consensus RatingMagenta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.33, Magenta Therapeutics has a forecasted upside of 837.7% from its current price of $0.46.Amount of Analyst CoverageMagenta Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.59% of the float of Magenta Therapeutics has been sold short.Short Interest Ratio / Days to CoverMagenta Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Magenta Therapeutics has recently decreased by 35.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMagenta Therapeutics does not currently pay a dividend.Dividend GrowthMagenta Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMagenta Therapeutics has received a 74.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Magenta Therapeutics is -0.84. Previous Next 1.4 News and Social Media Coverage News SentimentMagenta Therapeutics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Magenta Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for MGTA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added Magenta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Magenta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.18% of the stock of Magenta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.68% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Magenta Therapeutics are expected to grow in the coming year, from ($1.24) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Magenta Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Magenta Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMagenta Therapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Magenta Therapeutics (NASDAQ:MGTA) StockMagenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 2015 and is headquartered in Cambridge, MA.Read More Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTA Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comMagenta Therapeutics (NASDAQ:MGTA) Downgraded to "Neutral" at BTIG ResearchJanuary 27, 2023 | americanbankingnews.comMagenta Therapeutics (NASDAQ:MGTA) Earns "Market Perform" Rating from CowenJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 25, 2023 | marketwatch.comMagenta Therapeutics Dive 23% Following Participant Death in MGTA-117 TrialJanuary 25, 2023 | finance.yahoo.comMagenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug SafetyDecember 21, 2022 | finance.yahoo.comMagenta (MGTA) Down on Pipeline Update for Leukemia DrugDecember 20, 2022 | finance.yahoo.comMagenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer StudyDecember 20, 2022 | finance.yahoo.comMagenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical TrialJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 14, 2022 | benzinga.comShort Volatility Alert: Magenta TherapeuticsDecember 14, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR) and Magenta Therapeutics (MGTA)December 12, 2022 | finance.yahoo.comMagenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical TrialNovember 4, 2022 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Magenta Therapeutics (MGTA)November 3, 2022 | msn.comRecap: Magenta Therapeutics Q3 EarningsNovember 3, 2022 | finance.yahoo.comMagenta Therapeutics Reports Third Quarter Financial Results and Recent Program HighlightsNovember 3, 2022 | finance.yahoo.comMagenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual MeetingNovember 1, 2022 | finance.yahoo.comMagenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare ConferenceOctober 17, 2022 | finance.yahoo.comWe Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth CarefullyOctober 9, 2022 | msn.comDelhi Metro Update: Magenta line services disrupted between Botanical Garden to Jasola Vihar Shaheen BaghSeptember 17, 2022 | finance.yahoo.comMagenta Therapeutics, Inc. (MGTA)August 31, 2022 | nasdaq.comGreat week for Magenta Therapeutics, Inc. (NASDAQ:MGTA) institutional investors after losing 71% over the previous yearAugust 17, 2022 | finance.yahoo.comMagenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of DirectorsAugust 2, 2022 | finance.yahoo.comMagenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare ConferenceMay 17, 2022 | seekingalpha.comMagenta Therapeutics GAAP EPS of -$0.39May 16, 2022 | finance.yahoo.comMagenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program HighlightsMay 16, 2022 | finance.yahoo.comAfter Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)May 16, 2022 | finance.yahoo.comMagenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia TrialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTA Company Calendar Last Earnings11/03/2022Today1/28/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 242-0170FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.33 High Stock Price Forecast$8.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+837.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.80% Return on Assets-41.78% Debt Debt-to-Equity RatioN/A Current Ratio10.22 Quick Ratio10.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book0.16Miscellaneous Outstanding Shares60,560,000Free Float51,364,000Market Cap$27.98 million OptionableNot Optionable Beta2.12 Key ExecutivesJason GardnerPresident, Chief Executive Officer & DirectorStephen Frank MahoneyCOO, CFO, Treasurer & Chief Accounting OfficerLisa M. OlsonChief Scientific Officer & Head-ResearchDavid NicholsChief Technical OfficerJeffrey S. HumphreyChief Medical OfficerKey CompetitorsLumos PharmaNASDAQ:LUMOAdamis PharmaceuticalsNASDAQ:ADMPNovanNASDAQ:NOVNAeglea BioTherapeuticsNASDAQ:AGLEGeoVax LabsNASDAQ:GOVXView All CompetitorsInsiders & InstitutionsHellman Jordan Management Co. Inc. MABought 259,161 shares on 1/20/2023Ownership: 0.728%Alphabet Inc.Bought 3,339,138 shares on 11/16/2022Ownership: 5.514%Vanguard Group Inc.Bought 55,650 shares on 11/15/2022Ownership: 3.242%State Street CorpBought 12,500 shares on 11/15/2022Ownership: 0.230%Citadel Advisors LLCBought 40,259 shares on 11/15/2022Ownership: 0.066%View All Institutional Transactions MGTA Stock - Frequently Asked Questions Should I buy or sell Magenta Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares. View MGTA analyst ratings or view top-rated stocks. What is Magenta Therapeutics' stock price forecast for 2023? 5 analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their MGTA share price forecasts range from $2.00 to $8.00. On average, they predict the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 837.7% from the stock's current price. View analysts price targets for MGTA or view top-rated stocks among Wall Street analysts. How have MGTA shares performed in 2023? Magenta Therapeutics' stock was trading at $0.3950 at the beginning of the year. Since then, MGTA stock has increased by 17.0% and is now trading at $0.4621. View the best growth stocks for 2023 here. When is Magenta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our MGTA earnings forecast. How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP). When did Magenta Therapeutics IPO? (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Magenta Therapeutics' stock symbol? Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA." Who are Magenta Therapeutics' major shareholders? Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hellman Jordan Management Co. Inc. MA (0.73%). Insiders that own company stock include Bruce Booth and Kristen Stants. View institutional ownership trends. How do I buy shares of Magenta Therapeutics? Shares of MGTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Magenta Therapeutics' stock price today? One share of MGTA stock can currently be purchased for approximately $0.46. How much money does Magenta Therapeutics make? Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $27.98 million. The company earns $-71,140,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. How can I contact Magenta Therapeutics? Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.magentatx.com. The company can be reached via phone at (857) 242-0170 or via email at investor@magentatx.com. This page (NASDAQ:MGTA) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.